Cystic Fibrosis in Children Clinical Trial
Official title:
Effect of Antioxidant Docosahexaenoic Acid (DHA) Supplementation in Cystic Fibrosis Patients: A Randomized Placebo-controlled Trial
Verified date | June 2021 |
Source | Corporacion Parc Tauli |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the effect of antioxidant docosahexaenoic acid (DHA) in patients with cystic fibrosis. Half of participants will receive DHA, while the other half will receive placebo.
Status | Completed |
Enrollment | 22 |
Est. completion date | February 20, 2020 |
Est. primary completion date | February 20, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 18 Years |
Eligibility | Inclusion Criteria: - Patients of both genders with a diagnosis of cystic fibrosis. - FEV1 > 40%. - Age between 6 and 18 years. - Patients who grant their informed consent or whose representative grants informed consent to participate in the study. Exclusion Criteria: - Pregnant or breastfeeding women - Basal oxygen saturation <92% or household supplemental oxygen needs. - Massive hemoptysis - Patients who are not able to follow or who cannot be assessed in the study according to the protocol. - Any circumstance that, at the discretion of the doctor, may involve a clinical risk or harm, the patient's participation in the study or that interferes with the evaluation of the same. - Use of systemic glucocorticoids or in the 4 weeks prior to inclusion in the study. - Use of non-steroidal anti-inflammatory drugs in the 2 weeks prior to inclusion in the study. - Use of investigational drugs or participation in another clinical trial within 30 days prior to inclusion in the study or within the 5 elimination half-lives of the investigational drug. - Be already supplementing with Omega -3, fish oil or DHA |
Country | Name | City | State |
---|---|---|---|
Spain | Parc Tauli Hospital | Sabadell | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Corporacion Parc Tauli |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline Fatty Acid (FA) profile (percentage) of the erythrocyte membrane at 6 and 12 months | After blood sampling, erythrocytes are separated from the plasma by centrifugation (2500 rpm for 15 min) and stored at -80ºC until analysed. The fatty acids composition are analyzed by gas chromatography.
Fatty acid composition (SFA (saturated FA), MUFA (monoinsatured FA), PUFAs N-6 (polyunsaturated FA omega-6) and PUFAS N-3) are mesured as percentage of total fats. |
baseline, 6 month and 12 month of treatment (end of study) | |
Secondary | Change from Baseline Serum interleukins at 12 months | Serum are obtained by centrifugation of blood samples and frozen at -80ºC until testing.
Interleukins (IL)-1 ß, IL-6, IL-8 and tumor necrosis factor (TNF)-a (pg/ml) are analized in serum by enzyme-linked immunosorbent assay (ELISA kits). |
baseline and 12 month of treatment (end of study) | |
Secondary | Change from baseline pulmonary function at 3,6 ,9 and 12 months | Forced expiratory volume in 1 second (FEV1) , forced vital capacity (FVC) and 25-75% of the forced vital capacity (FEF25-75%) were mesured using spirometry, calibrated daily according to standardized techniques.
The results are expressed as the mean value of the percentage of predicted values according to height and sex and litres (L) |
baseline, 3 months, 6 month, 9 months and 12 month of treatment (end of study) | |
Secondary | Number of Pulmonary exacerbation during the study year compared with previous years | The investigators will report the number of pulmonary exacerbations during the previous year and the year of the study. To calculate the number of exacerbations, the medical records of the patients will be reviewed. | 12 months prior study, 12 months of the study | |
Secondary | Change from baseline fecal calprotectin at the 12 months | Calprotectin was measured in fecal samples of the participants. | Baseline and 12 months | |
Secondary | Adverse reactions during the study | Frequency of occurrence of adverse events related to the study treatment: diarrhea, steatorrhea, abdominal pain, nausea, vomiting, gastroesophageal reflux, fishy taste or hemorrhage. | baseline, 3, 6 , 9 and 12 month of treatment (end of study) | |
Secondary | Change from Baseline Esputum interleukins at 6 and 12 months | Supernatant induced sputum were frozen at -80ºC until testing. Induced sputum Interleukins (IL)-1 ß, IL-6, IL-8 and tumor necrosis factor (TNF)-a (pg/ml) were analized by enzyme-linked immunosorbent assay (ELISA kits). | baseline and 12 months | |
Secondary | Change from baseline differencial cell counts in sputum at 6 and 12 months. | An equal volume of sterile dithiothreitol (DTT), freshly diluted to 10% by the addition of sterile saline, was added to the sputum. This step was performed under a Bio-safety hood using sterile technique. The samples were then incubated in a shaking water bath at 37° C for 5-10 min, and gently mixed using a transfer pipette at 5-min intervals. The weight of the remaining sputum mixture was measured, and a further three times the volume of both DTT and phosphate-buffered saline (Dulbecco's; Gibco BRL, Grand Island, NY) were added. The mixture was incubated once again in the 37° C shaking water bath for another 5-10 min to ensure complete homogenization. Ten microliters of the homogenized sputum samples, mixed with Trypan Blue stain, was used to calculate total cell counts, using a standard hemacytometer. A further 0.25-0.50 ml of both samples was used to prepare cytospin slides for differential cell counts. | baseline, 6 months and 12 monts | |
Secondary | Change from baseline weight at 3, 6, 9 and 12 months | Weight in kilograms (kg) were measured every 3 months. Subjects dressed only in light underwear and shoeless. | Baseline, 3,6,9 and 12 months | |
Secondary | Change from baseline height at 3, 6, 9 and 12 months | Height was measured with a standardised statdiometer every 3months | Baseline, 3,6,9 and 12 months | |
Secondary | Change from baseline body mass index (BMI) at 3, 6, 9 and 12 months | BMI was calculate every 3 months. | Baseline, 3,6,9 and 12 months | |
Secondary | Change from Baseline FA ratios of the erythrocyte membrane at 6 and 12 months | The next fatty acids (FA) ratios were calculated:
Arachidonic acid /eicosapentaenoic acid (ARA/EPA) Arachidonic acid/ docosahexaenoic acid (ARA/DHA) N-3 PUFAS/ALA ( a-linolenic acid) N-6 PUFAS/LA (linoleic acid) |
baseline, 6 months and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Active, not recruiting |
NCT04602468 -
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)
|
Phase 4 | |
Completed |
NCT06109675 -
Nutritional Status Assessment of Pediatric Cystic Fibrosis Patients and Effect of Nutrition Education on Nutritional Status
|
N/A | |
Active, not recruiting |
NCT04392544 -
Intestinal Inflammation in CF Patients
|
||
Completed |
NCT04084041 -
Efficacy of Simeox Airway Clearance Therapy in Children With Cystic Fibrosis
|
N/A | |
Not yet recruiting |
NCT03292718 -
Clinical Trial to Assess Influence of MyCyFAPP Use on GI Related QOL in Children With Cystic Fibrosis
|
N/A | |
Not yet recruiting |
NCT05493137 -
Physical Activity Levels of Parents of Children With Cystic Fibrosis- (PHACTS-CF)
|
||
Enrolling by invitation |
NCT06188988 -
Viral Infections and Airway Microbiome in Young Children With Cystic Fibrosis
|
||
Recruiting |
NCT04174664 -
Comparison of Different Functional Capacity Tests in Cystic Fibrosis Patients With Acute Pulmonary Exacerbation
|
||
Completed |
NCT04138589 -
Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function
|
||
Completed |
NCT03579173 -
Determinants of Early Cystic Fibrosis Lung Disease
|
||
Recruiting |
NCT05850351 -
Virtual Reality Based Tele-Exercises on Exercise Capacity in Cystic Fibrosis
|
N/A | |
Completed |
NCT04463628 -
Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic
|
||
Completed |
NCT04835376 -
Percussion Palm Cup: Safety and Usability in Infants and Children With Cystic Fibrosis
|
N/A | |
Completed |
NCT04293926 -
Heart Rate Variability in Children and Adolescents With Cystic Fibrosis
|
N/A | |
Withdrawn |
NCT04415268 -
Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis
|
N/A | |
Not yet recruiting |
NCT06066723 -
19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
|
||
Terminated |
NCT03939065 -
Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management
|
N/A | |
Active, not recruiting |
NCT04613128 -
The PROMISE Pediatric Study 6 to 11 Years Old
|
||
Completed |
NCT06242951 -
Cardiopulmonary Fitness in Children With Cystic Fibrosis Compared to Healthy Children
|